The Loss of Exclusivity Planning Course for Pharma

THE CONTENT

With over $180 billion in pharmaceutical company revenues expected to lose exclusivity before 2030, some of the largest brands in the industry will face significant late-lifecycle challenges in the coming years.

Yet there is still limited understanding of what Loss of Exclusivity (LOE) really means among pharma professionals — and, more importantly, an underappreciation of the opportunities to continue delivering sustainable value for patients even in the face of generic or biosimilar competition.

This course provides a practical approach to understanding and preparing for LOE, rooted in real-life industry case studies & tangible examples of effective (and ineffective) LOE planning.

You will learn how to anticipate the likely impact of LOE, understand the diversity in how post-LOE dynamics evolve across global markets, and be introduced to the processes, frameworks, and tools that enable the effective navigation of LOE events.

THE EXPERTS

• Dr Neal Hansen
• James Kettlewell